MedMira granted patent for hepatitis C diagnostic

New York, Jan. 3 - MedMira Inc. said it has been granted a patent for its HCV mosaic antigen by the European Patent Office.

The Halifax, N.S., maker of diagnostic tests said the protection is the first on its rapid diagnostic technology in Europe, and paves the way for what it says is the world's first combination HIV and hepatitis C instant rapid test.

The HCV [hepatitis C] mosaic antigen is a highly immunoreactive mosaic antigen composition containing a plurality of different antigenic peptides encoded from the core region of the hepatitis C genome.

The patent also describes a test kit utilizing the antigen, and a method for its use for the purpose of detecting antibodies to hepatitis C in a test sample, MedMira said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.